Drug misuse a concern as new TB treatment faces delay in India

03/16/2013 | Business Standard (India)

Despite U.S. approval of bedaquiline drug Sirturo for treating multidrug-resistant tuberculosis, it faces potential delays in India, where the health minister says other research facilities are testing new TB treatments using bedaquiline. Experts are concerned that a culture of misuse that has rendered other drugs increasingly ineffective could do the same for bedaquiline in a country that, along with China, Russia and South Africa, represents 60% of MDR-TB cases in the world. "My biggest concern is you're introducing a brand new TB drug into one of the most unregulated chaotic drug markets you can see anywhere in the world," said Madhukar Pai, founder of the Pai Tuberculosis Research Group at Montreal's McGill University.

View Full Article in:

Business Standard (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA